Literature DB >> 20645015

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

Heidrun Karlic1, Harald Herrmann, Axel Schulenburg, Thomas W Grunt, Sylvia Laffer, Irina Mirkina, Rainer Hubmann, Medhat Shehata, Brigitte Marian, Edgar Selzer, Michael Pfeilstöcker, Elisabeth Pittermann, Ulrich Jäger, Hubert Pehamberger, Christoph Zielinski, Peter Valent.   

Abstract

Biological features of tumor cells relevant to progression, metastasis, and prognosis in cancer patients have been investigated for many years. During the past few years, the concept of tumor stem cells has gained widespread acceptance. The cancer stem cell (CSC) model is based on the observation that continuous growth of tumors depends on a small population of immature neoplastic cells with unlimited proliferative potential. In contrast to these CSC, more mature clonal cells in the same neoplasm undergo apoptosis and die after a variable number of cell divisions. The self-renewal capacity of CSC plays a central role in this scenario and enables permanent tumor cell repopulation in vivo in patients as well as in experimental animals, e.g., immunodeficient mice. Based on the stem cell concept, it is clear that the success of an anti-neoplastic approach depends on efficient targeting and elimination of CSC. An important aspect of CSC is their intrinsic resistance against conventional drugs. Therefore, a major focus in current research is molecular targets and their expression in CSC, with the goal to use targeted drugs for CSC elimination. It is the hope for the future that therapeutic approaches involving CSC-targeting concepts will lead to sustained remission and thus improvement of prognosis in leukemia and cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645015     DOI: 10.1007/s00508-010-1408-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  115 in total

1.  Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.

Authors:  Tin Lap Lee; Jason Yeh; Carter Van Waes; Zhong Chen
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

Review 2.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Authors:  Riccardo Fodde; Thomas Brabletz
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

3.  Nonredundant roles for Runx1 alternative promoters reflect their activity at discrete stages of developmental hematopoiesis.

Authors:  Thomas Bee; Gemma Swiers; Sawako Muroi; Amir Pozner; Wade Nottingham; Ana Cristina Santos; Pik-Shan Li; Ichiro Taniuchi; Marella F T R de Bruijn
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

4.  Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia.

Authors:  M D Minden; R N Buick; E A McCulloch
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

5.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

Review 6.  Cancer stem cells and human malignant melanoma.

Authors:  Tobias Schatton; Markus H Frank
Journal:  Pigment Cell Melanoma Res       Date:  2008-02       Impact factor: 4.693

7.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  The incidence of recurrence of leukemia in donor cells after allogeneic bone marrow transplantation.

Authors:  C N Boyd; R C Ramberg; E D Thomas
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

Review 10.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  4 in total

1.  Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.

Authors:  Shenxu Wang; Sai Ma; Xiujuan Li; Zengfu Xue; Xiaotian Zhang; Weiwei Fan; Yongzhan Nie; Kaichun Wu; Xiaoyuan Chen; Feng Cao
Journal:  Exp Lung Res       Date:  2014-08-25       Impact factor: 2.459

Review 2.  [Cancer stem cells as the therapeutic target of tomorrow].

Authors:  Jiří Hatina
Journal:  Wien Med Wochenschr       Date:  2016-03-04

3.  Similarity on neural stem cells and brain tumor stem cells in transgenic brain tumor mouse models.

Authors:  Guanqun Qiao; Qingquan Li; Gang Peng; Jun Ma; Hongwei Fan; Yingbin Li
Journal:  Neural Regen Res       Date:  2013-09-05       Impact factor: 5.135

Review 4.  Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Authors:  Peter Valent; Emir Hadzijusufovic; Thomas Grunt; Heidrun Karlic; Barbara Peter; Harald Herrmann; Gregor Eisenwort; Gregor Hoermann; Axel Schulenburg; Michael Willmann; Rainer Hubmann; Medhat Shehata; Edgar Selzer; Karoline V Gleixner; Thomas Rülicke; Wolfgang R Sperr; Brigitte Marian; Michael Pfeilstöcker; Hubert Pehamberger; Felix Keil; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2018-07-13       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.